Lirafugratinib

N/A

Report date: 2026/04/02 10:52:45
NME

Base Information

Drug NameLirafugratinib
Drug Alias NameRLY-4008
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 2 inhibitors
TargetsFibroblast growth factor receptor 2
Therapy Area/IndicationsSolid tumoursTranslocation, GeneticCholangiocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeSweden +[13
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesRelay Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesElevar Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursTranslocation, GeneticCholangiocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A